Zydus Lifesciences will be in focus on Wednesday after receiving final USFDA approval for its Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg, and 240 mg strengths. The drug, a generic version of Calan SR, is used to treat high blood pressure. The approval strengthens Zydus’ US portfolio and supports its ongoing expansion in the regulated markets.
Zydus Lifesciences shares in focus after USFDA nod for Verapamil Hydrochloride ER Tablets
📅 Published: November 26, 2025 |
📂 Category: Uncategorized